INTRODUCTION: Continuous infusion of levodopa/carbidopa intestinal gel (LCIG) is an effective treatment for @entity1 with advanced @entity191 ( @entity191 ) that cannot be further improved by oral therapy. METHODS: We conducted an observational, prospective, and multicenter study to collect, in a large sample of @entity191 treated with LCIG, long-term information about the outcome and safety of the treatment. The assessments were performed before LCIG, 1, 3, 6 months after, and ever since, every 6 months. RESULTS: We studied 72 @entity1 with a mean observation time of 22 months and a maximum of 48 months. During follow-up 28 @entity1 discontinued the treatment, especially for lack of efficacy or adverse events related to the drug. We obtained a significant improvement of motor and non-motor fluctuations, mean off time and some non-motor symptoms. A significant increase in the percentage of time with @entity910 was found in @entity1 having less than 50% of the day with @entity910 before LCIG. However, @entity1 having already many @entity910 before LCIG experienced a significant decrease of the troublesome @entity910 , meaning that outcomes might be different depending on specific clinical characteristics. Adverse effects were in general minor but one case of intestinal perforation and one of abdominal cellulite were observed. CONCLUSIONS: We confirmed that LCIG is a very effective treatment option for advanced @entity191 ; however considering the findings that @entity910 can increase and the potential for serious side effects, we suggest the necessity for development of guidelines that better define the profile of responders.

Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in @entity1 with advanced XXXX : The Barcelona registry.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity910 :: ('MESH:D004409', 'Disease') :: ['dyskinesia', 'dyskinesias'] @entity191 :: ('MESH:D010300', 'Disease') :: ['PD', 'Parkinson Disease']
@entity191 :: (MESH:D010300,Disease) :: ['Parkinson disease']
